Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 11:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–64 of 64 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cancer vaccine plus immune adjuvant Clear all

Conditions: Mesolthelioma, Esophageal Cancer, Lung Cancer, Thoracic Sarcomas, Thymoma
Interventions: Celebrex, Tumor cell vaccine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bladder Cancer
Interventions: CDX-1307 Vaccine Regimen, Chemotherapy; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 17
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 13 more

Conditions: Glioma, Malignant
Interventions: Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine, Hiltonol; Biological · Drug
Lead sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Cancer
Interventions: rsPSMA protein plus Alhydrogel® vaccine; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: GPI-0100, MUC-2-Globo H-KLH conjugate vaccine; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
Interventions: Cancer vaccine plus immune adjuvant; Biological
Lead sponsor: TVAX Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: SARS-CoV Infection
Interventions: COVID-19 vaccine; Biological
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancies
Interventions: Cyclophosphamide, Allogenic tumor Cell Vaccine (K562), Celecoxib; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: Personalized Synthetic Long Peptide Vaccine; Biological
Lead sponsor: Jaime Leandro Foundation for Therapeutic Cancer Vaccines; Other
Eligibility: 12 Years and older
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Melanoma
Interventions: Leuprolide, GP100: 209-217(210M) Peptide, MAGE-3 Peptide; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Risk for Colorectal Cancer
Interventions: MUC1 - Poly ICLC; Biological
Lead sponsor: Robert Schoen; Other
Eligibility: 40 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
Interventions: FK-PC101, Standard of Care (SOC); Biological
Lead sponsor: Cellvax Therapeutics Inc; Industry
Eligibility: Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • Gahanna, Ohio • Myrtle Beach, South Carolina

Conditions: Breast Cancer, HER2-positive Breast Cancer
Interventions: HER2 Vaccine; Drug
Lead sponsor: Pravin T.P Kaumaya; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Urinary Bladder Cancer, Bladder Tumors, Transitional Cell Carcinoma of the Bladder, Malignant Melanoma, Melanoma, Skin Cancer, Carcinoma, Non-Small-Cell Lung, Lung Cancer
Interventions: NEO-PV-01, Nivolumab, Adjuvant; Biological · Other
Lead sponsor: BioNTech US Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 4 more

Conditions: Lymphoma
Interventions: autologous tumor cell vaccine, keyhole limpet hemocyanin, sargramostim, adjuvant therapy; Biological · Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Urothelial Carcinoma
Interventions: DN24-02, Standard of Care; Biological · Other
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 60
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more

Search by objective public record fields.

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM

Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel

Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer

Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma

COVID-19 Vaccine Response in Chronic Respiratory Conditions

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

Melanoma Vaccine With Peptides and Leuprolide

Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

HER2 Vaccine for Locally Advanced Breast Cancer

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma